Five–year risk of incident pancreatic cancer in patients with type 2 diabetes
(Comparison between propensity–score matched cohorts: GLP–1RA combination therapy vs monotherapy)

Size/group	Exposure group	Comparison group	# of cases (overall risk) (Exposure group)	# of cases (overall risk) (Comparison group)		HR (95% CI)
GLP–1RA(+)DRUG(+) vs DRUG(+)GLP–1RA(−)						
84,806	GLP–1RA(+)Insulin(+)	Insulin(+)GLP–1RA(−)	373 (0.44%)	408 (0.48%)		0.80 (0.70–0.92)
72,540	GLP–1RA(+)Metformin(+)	Metformin(+)GLP–1RA(−)	239 (0.33%)	273 (0.38%)		0.81 (0.68–0.96)
22,517	GLP–1RA(+)DDP–4(+)	DPP–4(+)GLP–1RA(−)	74 (0.33%)	83 (0.37%)		0.77 (0.56–1.05)
39,542	GLP–1RA(+)SGLT2(+)	SGLT2(+)GLP–1RA(−)	104 (0.26%)	175 (0.44%)		0.49 (0.38–0.62)
44,289	GLP–1RA(+)SU(+)	SU(+)GLP–1RA(−)	160 (0.36%)	170 (0.38%)		0.84 (0.68–1.04)
17,177	GLP–1RA(+)TZD(+)	TZD(+)GLP–1RA(−)	55 (0.32%)	60 (0.35%)		0.81 (0.56–1.17)
GLP–1RA(+)DRUG(+) vs GLP–1RA(+)DRUG(−)						
44,157	GLP–1RA(+)Insulin(+)	GLP–1RA(+)Insulin(−)	188 (0.43%)	87 (0.20%)		2.01 (1.56–2.60)
26,405	GLP–1RA(+)Metformin(+)	GLP–1RA(+)Metformin(−)	91 (0.35%)	77 (0.29%)		1.08 (0.80–1.46)
18,993	GLP–1RA(+)DDP–4(+)	GLP–1RA(+)DPP–4(−)	55 (0.29%)	59 (0.31%)		0.88 (0.61–1.27)
54,413	GLP–1RA(+)SGLT2(+)	GLP–1RA(+)SGLT2(−)	129 (0.24%)	126 (0.23%)		0.96 (0.75–1.23)
29,164	GLP–1RA(+)SU(+)	GLP–1RA(+)SU(−)	96 (0.33%)	83 (0.29%)		1.08 (0.81–1.45)
15,255	GLP–1RA(+)TZD(+)	GLP–1RA(+)TZD(−)	45 (0.30%)	34 (0.22%)		1.27 (0.81–1.98)

Hazard Ratio (HR)

0.30 0.40 0.50 0.70 0.90 2.0 3.00